Moderna’s shares experienced a significant drop of up to 25% on Thursday following the leak of partial data concerning its cancer vaccine, developed in collaboration with Merck. Despite the overall positive reception of the full data release later that day, both companies saw declines in their stock prices. The personalized cancer vaccine, named intismeran autogene, combined with Merck’s Keytruda immunotherapy, showed promising results. It reduced the risk of recurrence or death by 42% in certain melanoma patients compared to Keytruda alone. Additionally, it lowered the risk of cancer spreading or mortality by 38% when used in tandem with Keytruda.
Clinical results indicated that 82% of patients receiving the personalized vaccine alongside Keytruda were alive without melanoma recurrence two years post-treatment, compared to 70% for those treated with Keytruda only. Dr. Hussein Tawbi from the University of Texas MD Anderson Cancer Center described this as a major advancement, noting that the side effects were comparatively mild. With a planned presentation of detailed phase 3 trial results at the European Society for Medical Oncology conference this weekend, Dr. Dean Li, president of Merck Research Laboratories, emphasized the evidence of additional benefits from the vaccine.
Despite elevated investor expectations, analysts maintained that the observed data was clinically meaningful. The companies are exploring further applications of the vaccine for other cancer types, including lung and bladder cancers. However, the unique manufacturing process for the personalized vaccine poses challenges, with Merck seeking to expedite production timelines in the future.
Why this story matters:
- The collaboration between Moderna and Merck could lead to significant advancements in cancer treatment.
Key takeaway:
- The personalized cancer vaccine shows promise in treating melanoma, potentially setting a foundation for broader applications against various types of cancer.
Opposing viewpoint:
- Stock market reactions suggest that investor expectations may have been inflated relative to the clinical data released.
